DCVax®-L as a potential vaccine against glioblastoma

Northwest Biotherapeutics (MD, USA) have announced the publication of interim, blinded survival data from its Phase III clinical trial of DCVax®-L for newly diagnosed glioblastoma. Researchers believe that addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients and may extend survival. The interim data have been published in the Journal of Translational Medicine and the trial is currently ongoing while data continue to mature. The company, investigators and patients all remain blinded. The study included data from patients in both arms of the trial combined: those receiving standard of care plus DCVax-L and those receiving standard...